Health · 1 sources covering this

STAT+: Pharmalittle: We’re reading about the FDA commissioner nominee, a Lilly partnership in China, and more

During a Senate hearing today, Heidi Overton, the nominee to lead the FDA, plans to emphasize the need for speed and efficiency to compete with China

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·2h ago
STAT+: Pharmalittle: We’re reading about the FDA commissioner nominee, a Lilly partnership in China, and more
During a Senate hearing today, Heidi Overton, the nominee to lead the FDA, plans to emphasize the need for speed and efficiency to compete with China
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/2ea6c6b61097e7d7e2948e29cb219474a7f39a84"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: Pharmalittle: We&#8217;re reading about the FDA commissioner nominee, a Lilly partnership in China, and more"></iframe>

STAT+: Pharmalittle: We’re reading about the FDA commissioner nominee, a Lilly partnership in China, and more

How 1 sources are covering this

STAT+: Pharmalittle: We’re reading about the FDA commissioner nominee, a Lilly partnership in China, and more

More from Health

STAT+: Indonesian ruling against ‘patent evergreening’ by pharma industry sends critical message, patient advocates say

STAT+: Kyverna’s cell therapy shows lasting autoimmune benefit

STAT+: The rise of the AI-native radiology practice

One of the most contagious diseases on the planet is having its worst U.S. outbreak since 1991

Reader

Trust & legal

Across the network

How 1 sources are covering this

STAT+: Pharmalittle: We&#8217;re reading about the FDA commissioner nominee, a Lilly partnership in China, and more

More from Health

STAT+: Indonesian ruling against &#8216;patent evergreening&#8217; by pharma industry sends critical message, patient advocates say

STAT+: Kyverna&#8217;s cell therapy shows lasting autoimmune benefit

STAT+: The rise of the AI-native radiology practice

One of the most contagious diseases on the planet is having its worst U.S. outbreak since 1991

Reader

Trust & legal

Across the network

STAT+: Pharmalittle: We’re reading about the FDA commissioner nominee, a Lilly partnership in China, and more

STAT+: Indonesian ruling against ‘patent evergreening’ by pharma industry sends critical message, patient advocates say

STAT+: Kyverna’s cell therapy shows lasting autoimmune benefit